These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 20975357)

  • 1. What surveillance plan should be advised for patients in remission after completion of first-line therapy for advanced ovarian cancer?
    Rustin GJ
    Int J Gynecol Cancer; 2010 Oct; 20(11 Suppl 2):S27-8. PubMed ID: 20975357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Audit of CA125 Follow-Up After First-Line Therapy for Ovarian Cancer.
    Krell D; Said Battistino F; Benafif S; Ganegoda L; Hall M; Rustin GJS
    Int J Gynecol Cancer; 2017 Jul; 27(6):1118-1122. PubMed ID: 28333841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treated ovarian cancer: comparison of MR imaging with serum CA-125 level and physical examination--a longitudinal study.
    Low RN; Saleh F; Song SY; Shiftan TA; Barone RM; Lacey CG; Goldfarb PM
    Radiology; 1999 May; 211(2):519-28. PubMed ID: 10228537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fifth Alon Dembo memorial workshop: case 3.
    Schwartz PE
    Int J Gynecol Cancer; 2010 Oct; 20(11 Suppl 2):S24-6. PubMed ID: 20975356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of regular physical examination in the detection of ovarian cancer recurrence.
    Chan KK; Tam KF; Tse KY; Ngan HY
    Gynecol Oncol; 2008 Aug; 110(2):158-61. PubMed ID: 18544459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the cost of CA-125 measurement, physical exam, and imaging in the diagnosis of recurrent ovarian cancer.
    Armstrong A; Otvos B; Singh S; Debernardo R
    Gynecol Oncol; 2013 Dec; 131(3):503-7. PubMed ID: 24060416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of FDG PET-CT in asymptomatic epithelial ovarian cancer with rising serum CA-125: a pilot study.
    Ghosh J; Thulkar S; Kumar R; Malhotra A; Kumar A; Kumar L
    Natl Med J India; 2013; 26(6):327-31. PubMed ID: 25073988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of CA-125 Tests and Computed Tomographic Scans for Surveillance in Ovarian Cancer.
    Esselen KM; Cronin AM; Bixel K; Bookman MA; Burger RA; Cohn DE; Cristea M; Griggs JJ; Levenback CF; Mantia-Smaldone G; Meyer LA; Matulonis UA; Niland JC; Sun C; O'Malley DM; Wright AA
    JAMA Oncol; 2016 Nov; 2(11):1427-1433. PubMed ID: 27442965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer: a preliminary investigation.
    Wilder JL; Pavlik E; Straughn JM; Kirby T; Higgins RV; DePriest PD; Ueland FR; Kryscio RJ; Whitley RJ; Nagell Jv
    Gynecol Oncol; 2003 May; 89(2):233-5. PubMed ID: 12713985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Routine Cancer Antigen 125 Surveillance-The Fatal Attraction of Testing.
    Goodwin JS
    JAMA Oncol; 2016 Nov; 2(11):1412-1413. PubMed ID: 27442246
    [No Abstract]   [Full Text] [Related]  

  • 11. Post-therapy surveillance and after-care in ovarian cancer.
    von Georgi R; Schubert K; Grant P; Münstedt K
    Eur J Obstet Gynecol Reprod Biol; 2004 Jun; 114(2):228-33. PubMed ID: 15140520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of PET/CT in the management of recurrent ovarian cancer.
    Simcock B; Neesham D; Quinn M; Drummond E; Milner A; Hicks RJ
    Gynecol Oncol; 2006 Oct; 103(1):271-6. PubMed ID: 16626793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ultrasound, physical examination, and CA 125 measurement for the detection of recurrence after conservative surgery for early borderline ovarian tumors.
    Zanetta G; Rota S; Lissoni A; Meni A; Brancatelli G; Buda A
    Gynecol Oncol; 2001 Apr; 81(1):63-6. PubMed ID: 11277651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Duration of second or greater complete clinical remission in ovarian cancer: exploring potential endpoints for clinical trials.
    Harrison ML; Gore ME; Spriggs D; Kaye S; Iasonos A; Hensley M; Aghajanian C; Venkatraman E; Sabbatini P
    Gynecol Oncol; 2007 Sep; 106(3):469-75. PubMed ID: 17614127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CA125 based diagnosis and therapy in recurrent ovarian cancer.
    Meier W; Baumgartner L; Stieber P; Hasholzner U; Fateh-Moghadam A
    Anticancer Res; 1997; 17(4B):3019-20. PubMed ID: 9329590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The quest for ovarian cancer's Holy Grail: can CA-125 still be the chalice of early detection?
    Karlan BY; McIntosh M
    J Clin Oncol; 2007 Apr; 25(11):1303-4. PubMed ID: 17416848
    [No Abstract]   [Full Text] [Related]  

  • 17. Utility of PET/CT in the diagnosis of recurrent ovarian cancer depending on CA 125 serum level.
    Fularz M; Adamiak P; Czepczyński R; Jarząbek-Bielecka G; Rewers A; Kędzia W; Ruchała M
    Nuklearmedizin; 2015; 54(4):158-62. PubMed ID: 26076719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Follow-up after the treatment of ovarian cancer - really without Ca 125?].
    Freitag P
    Ceska Gynekol; 2012 Dec; 77(6):540-2. PubMed ID: 23521196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Follow-up of ovarian and primary peritoneal carcinoma: the value of physical examination in patients with pretreatment elevated CA125 levels.
    Menczer J; Chetrit A; Sadetzki S; Golan A; Levy T
    Gynecol Oncol; 2006 Oct; 103(1):137-40. PubMed ID: 16564077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of CA125, physical and radiological findings in follow-up of ovarian cancer patients.
    Fehm T; Heller F; Krämer S; Jäger W; Gebauer G
    Anticancer Res; 2005; 25(3A):1551-4. PubMed ID: 16033059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.